At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
INAB IN8bio, Inc.
Pre-Market Trading 05-24 04:54:43 EDT
1.04
-0.01
-0.96%
High1.05
Low1.02
Vol23.11K
Open1.03
D1 Closing1.05
Amplitude3.15%
Mkt Cap45.78M
Tradable Cap23.98M
Total Shares44.02M
T/O23.84K
T/O Rate0.10%
Tradable Shares23.06M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting
IN8bio, Inc., a clinical-stage biotechnology company, focuses on developing novel therapies for the treatment of cancers, including solid tumors using allogeneic, autologous, and genetically modified gamma-delta T cells. It is conducting two investigator-initiated Phase 1 clinical product candidates comprising INB-200, a genetically modified autologous gamma-delta T cell product candidate for the treatment of solid tumors; and INB-100, an allogeneic product candidate for the treatment of patients with acute leukemia undergoing hematopoietic stem cell transplantation. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was founded in 2016 and is based in New York, New York.